Grifols (GRFS) EPS (Basic) Growth (1y) (2011 - 2020)
Grifols (GRFS) EPS (Basic) Growth (1y) (2011 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.91 Bn | 632.15 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 469.40 Bn | 462.83 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 375.75 Bn | 368.61 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 303.13 Bn | 295.44 Bn | 11.24 Bn | -92.05% |
| 5 | Astrazeneca | 257.65 Bn | 252.75 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 236.26 Bn | 222.27 Bn | 7.24 Bn | 65.24% |
| 7 | Gilead Sciences | 182.12 Bn | 178.95 Bn | 6.22 Bn | -636.10% |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | -108.11% |
| 9 | Gsk | 106.21 Bn | 102.04 Bn | 8.24 Bn | -69.49% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 69.31% |
| Dec 31, 2019 | -7.68% |
| Mar 31, 2019 | -26.29% |
| Dec 31, 2018 | -9.13% |
| Jun 30, 2018 | 1.99% |
| Mar 31, 2018 | 6.41% |
| Dec 31, 2017 | 485.53% |
| Jun 30, 2017 | 25.83% |
| Mar 31, 2017 | -34.97% |
| Dec 31, 2016 | 5.21% |
| Sep 30, 2016 | 1.73% |
| Jun 30, 2016 | 38.34% |
| Mar 31, 2016 | 163.37% |
| Dec 31, 2015 | -75.59% |
| Sep 30, 2015 | -65.56% |
| Jun 30, 2015 | -52.64% |
| Mar 31, 2015 | -12.98% |
| Dec 31, 2014 | 24.17% |
| Sep 30, 2014 | 305.43% |
| Jun 30, 2014 | 158.99% |